• Alias: AZD9291
    • An orally available, irreversible, third-generation, mutant-selective EGFR inhibitor that selectively and covalently binds to and inhibits the activity of the mutant forms of EGFR, including the T790M EGFR mutant form, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells.
    • FDA approved for metastatic NSCLC with EGFR T790 mutation–positive patients who have progressed on or after EGFR TKI therapy
    • Recommended dose: 80 mg daily with or without food. May be dissolved in water if needed
    • Metabolism: Major CYP3A4 substrate
    • Half-life: â™48 hours
    Other topics in Targeted and Immunotherapy Agents